Novartis’ Multiple Sclerosis drug is effective for up to six years, study reveals
Swiss drugmaker Novartis recently announced five-year efficacy data on its monoclonal antibody to treat Multiple Sclerosis. According to the data, these efficacy outcomes included 44 percent fewer relapses 96.4 percent and 82.7 percent reductions in MRI …